Literature DB >> 12034147

How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journey.

John G F Cleland1.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12034147     DOI： 10.1016/s1388-9842(02)00039-9

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


× No keyword cloud information.
  9 in total

1.  Patients with treatable malignant diseases--including heart failure--are entitled to specialist care.

Authors:  John G F Cleland
Journal:  CMAJ       Date:  2005-01-18       Impact factor: 8.262

Review 2.  Dobutamine stress echocardiography: does it predict response to beta-blockers in patients with heart failure?

Authors:  Sripal Bangalore; Khashayar Hematpour; Farooq A Chaudhry
Journal:  Curr Heart Fail Rep       Date:  2006-06

Review 3.  Are all outcomes in chronic heart failure rated equally? An argument for a patient-centred approach to outcome assessment.

Authors:  Sungwon Chang; Phillip J Newton; Sally Inglis; Tim Luckett; Henry Krum; Peter Macdonald; Patricia M Davidson
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

Review 4.  The determinants of clinical outcome and clinical response to CRT are not the same.

Authors:  John G F Cleland; Stefano Ghio
Journal:  Heart Fail Rev       Date:  2012-11       Impact factor: 4.214

5.  Preoperative ANemiA among the elderly undergoing major abdominal surgery (PANAMA) study: Protocol for a single-center observational cohort study of preoperative anemia management and the impact on healthcare outcomes.

Authors:  Hairil Rizal Abdullah; Yilin Eileen Sim; Yi Tian Mary Sim; Ecosse Lamoureux
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

6.  Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.

Authors:  Milton Packer; Javed Butler; Faiez Zannad; Gerasimos Filippatos; Joao Pedro Ferreira; Stuart J Pocock; Peter Carson; Inder Anand; Wolfram Doehner; Markus Haass; Michel Komajda; Alan Miller; Steen Pehrson; John R Teerlink; Sven Schnaidt; Cordula Zeller; Janet M Schnee; Stefan D Anker
Journal:  Circulation       Date:  2021-08-29       Impact factor: 29.690

7.  Rationale and design of a risk-guided strategy for reducing readmissions for acute decompensated heart failure: the Risk-HF study.

Authors:  Georgios Zisis; Quan Huynh; Yang Yang; Christopher Neil; Melinda J Carrington; Jocasta Ball; Graeme Maguire; Thomas H Marwick
Journal:  ESC Heart Fail       Date:  2020-07-22

8.  Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.

Authors:  Milton Packer; Stefan D Anker; Javed Butler; Gerasimos Filippatos; João Pedro Ferreira; Stuart J Pocock; Peter Carson; Inder Anand; Wolfram Doehner; Markus Haass; Michel Komajda; Alan Miller; Steen Pehrson; John R Teerlink; Martina Brueckmann; Waheed Jamal; Cordula Zeller; Sven Schnaidt; Faiez Zannad
Journal:  Circulation       Date:  2020-10-21       Impact factor: 29.690

Review 9.  Endpoints in Heart Failure Drug Development.

Authors:  Aliza Hussain; Arunima Misra; Biykem Bozkurt
Journal:  Card Fail Rev       Date:  2022-01-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.